u/burned_once_twice

Read the phase 2 paper twice before ordering anything.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Contemporaneous or reconstructed?

What is the one column you added late and wish you had from the start?

Did anything else change in the window you are asking about?

research-use-only material is not approved for human use, full stop

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

What did the repeat show?

The confounding problem, stated plainly, because this board keeps stepping on it.

This is the sentence to read before anybody panics about a single value.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

the TRIUMPH programme is still running, so anything definitive is premature

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

shortage status changes and the whole arrangement changes with it

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

Cosigning on baseline. The panel I regret most is the one I did not take before starting.

dose escalation in the trials was slow for a reason

Cosigning that going too fast is the most repeated regret on the whole site.

How long have you been logging?

Same lab as the previous draw?

What did the repeat show?

Did anything else change in that window — training, intake, hydration?

How many weeks between the two measurements?

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

comparing reta phase 2 to sema phase 3 is comparing different things

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Sent a vial to Medutest out of curiosity. Result was 99.5% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.

The five questions worth asking before you commit to any compounded arrangement.

Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.

All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.

The constipation profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.